Understanding genetic variations is important in predicting the treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for the treatment of psoriasis. Limited data are available for the efficacy of secukinumab in relation to genetic markers. Patients (434) were recruited: 185 (42.6%) were Cw6‐POS, and 246 (56.7%) were Cw6‐NEG (3 not assessed). The mean age was 45.2±13.2 years (Cw6‐POS, 42.7±13.1; Cw6‐NEG, 47.2±12.9).